Rallybio Corporation (RLYB)
RLYB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/0001628280-26-018261-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RLYB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001739410 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $858K |
| Net income | -$9.0M |
| Operating income | -$33.1M |
| Net margin | -1046.4% |
| Operating margin | -3853.6% |
| Revenue growth | +34.9% |
| Cash | $31.4M |
| Total assets | $62.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 100.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-27 |
| Cash and burn | $90.7M cash; operating cash flow $7.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 5,383,937 (2026-10-20); 42,243,774 a year earlier; 37,793,705 three years earlier. 1y figure adjusted for split (1-for-8 overall); 3y figure adjusted for split (1-for-8 overall). | Cover page 2026-10-20 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2026-02-06 | Source 2026-02-06 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Hartford, Connecticut, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4.2M, sold $4K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$2.7M | -$2.3M | $90.7M | No debt tags | $434K | 10-Q 2026-10-27 |
| Q2 2026 2026-06-30 | $0 | $43.7M | $45.9M | $92.8M | No debt tags | $646K | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $212K | -$8.3M | -$8.0M | $41.3M | No debt tags | $858K | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $222K | -$5.9M | -$4.7M | $31.4M | No debt tags | $858K | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $212K | $16.0M | -$6.5M | $32.1M | No debt tags | $674K | 10-Q 2026-10-27 |
| Q2 2025 2025-06-30 | $212K | -$9.7M | -$8.4M | $9.4M | No debt tags | $761K | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $212K | -$9.4M | -$10.2M | $14.8M | No debt tags | $848K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $38K | -$11.0M | -$9.9M | $13.9M | No debt tags | $636K | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-15 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-10-27 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-01-02 |
Source: SEC EDGAR submissions feed, 314 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.2% |
| 1 month | -6.0% |
| 3 months | -7.3% |
| Year to date | +186.4% |
| 1 year | +199.5% |
| From 52-week high | -8.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
| GNLX | Genelux Corporation | $1.92 | +2.95% | $86.9M |
| KZIA | Kazia Therapeutics Limited | $5.60 | -15.41% | $87.1M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| PLYX | Polaryx Therapeutics Inc. | $1.67 | -6.99% | $83.2M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier